The impact of depression symptoms on postmorbid adaptation of patients who have undergone SARS-CoV-2 infection (assessment from the position of the multimorbidity model)

Barkhatova A.N.; Sorokin S.A.; Bolgov M.I.; Smolnikova A.O.

doi:https://doi.org/10.17116/jnevro202312303170

Barkhatova A.N.

Mental Health Research Center

Sorokin S.A.

Mental Health Research Center

Bolgov M.I.

Mental Health Research Center

Smolnikova A.O.

Mental Health Research Center

The impact of depression symptoms on postmorbid adaptation of patients who have undergone SARS-CoV-2 infection (assessment from the position of the multimorbidity model)

Authors:

Barkhatova A.N., Sorokin S.A., Bolgov M.I., Smolnikova A.O.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(3): 70‑74

DOI: 10.17116/jnevro202312303170

Read: 2032 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Barkhatova AN, Sorokin SA, Bolgov MI, Smolnikova AO. The impact of depression symptoms on postmorbid adaptation of patients who have undergone SARS-CoV-2 infection (assessment from the position of the multimorbidity model). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(3):70‑74. (In Russ.)
https://doi.org/10.17116/jnevro202312303170

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the impact of psychosomatic and anxiety symptoms of depression on the formation of postmorbid adaptation in patients who have undergone SARS-CoV-2 infection.

MATERIAL AND METHODS

The data of 54 patients, aged 18—55 years, with a current depressive episode who had outpatient SARS-CoV-2 infection were analyzed. The Hamilton depression rating scale (HDRS) was used and somatic condition was assessed using a general assessment of the patient’s function limitation at the stage of reconvalescence. A linear regression analysis was performed to assess the association of psychosomatic and anxiety symptoms with somatic condition in SARS-CoV-2 infection, regardless of other factors.

RESULTS

The multimorbidity model took into account, in addition to SARS-CoV-2 caused by organic somatic disorders, psychosomatic manifestations (B=–1.9, p=0.004) and anxiety (B=–3.7, p=0.04) symptoms of depression. Somatic anxiety was significantly correlated with a pronounced impairment of postmorbid readaptation (p<0.05), while mental anxiety did not demonstrate such a relationship (p=0.46). The observed trend seems to be due to the overlap of manifestations of somatic anxiety with the construct of residual somatic symptoms, even though there is no multicollinearity between them.

CONCLUSION

Identification of clusters of symptoms associated with reduced opportunities for full recovery in the SARS-CoV-2-postmorbid period can significantly help in providing a high-quality and targeted psychopharmacological care.

Keywords:

SARS-CoV-2 infection

postmorbid adaptation

depression

anxiety

somatic symptoms

multimorbidity

Authors:

Barkhatova A.N.

Mental Health Research Center

Sorokin S.A.

Mental Health Research Center

Bolgov M.I.

Mental Health Research Center

Smolnikova A.O.

Mental Health Research Center

Received:

25.11.2022

Accepted:

07.12.2022

Close metadata

References:

Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. Journal of Chronic Diseases. 1970;23(7):455-468. https://doi.org/10.1016/0021-9681(70)90054-8
van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what’s in a name? A review of the literature. European Journal General Practice. 1996;2:65-70. https://doi.org/10.3109/13814789609162146
Valderas JM, Starfield B, Sibbald B, et al. Defining Comorbidity: implications for Understanding Health and Health Services. The Annals of Family Medicine. 2009;7(4):357-363. https://doi.org/10.1370/afm.983
Whitty CJM, MacEwen C, Goddard A, et al. Rising to the challenge of multimorbidity. British Medical Journal. 2020;368:16964. https://doi.org/10.1136/bmj.l6964
Meghani SH, Buck HG, Dickson VV, et al. The Conceptualization and Measurement of Comorbidity: A Review of the Interprofessional Discourse. Nursing Research and Practice. 2013;2013:192782. https://doi.org/10.1155/2013/192782
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases. 1987;40(5):373-342. https://doi.org/10.1016/0021-9681(87)90171-8
Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. Journal of the American Geriatrics Society. 1968;16(5):622-626. https://doi.org/10.1111/j.1532-5415.1968.tb02103.x
Avedisova AS, Zhabin MO, Akzhigitov RG, Gudkova AA. The problem of multiple somatic and/or psychiatric pathology basic concepts and prevalence. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(5):5-13. (In Russ.). https://doi.org/10.17116/jnevro2018118515
Kanorskii SG. Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kubanskii Nauchnyi Meditsinskii Vestnik. 2021;28(6):90-116. (In Russ.). https://doi.org/10.25207/1608-6228-2021-28-6-90-116
Nalbandian A, Sehgal K, Gupta K, et al. Post-acute COVID-19 syndrome. Natural Medicine. 2021;27(4):601-615. https://doi.org/10.1038/s41591-021-01283-z
Mosolov SN. Problems of mental health in the situation of COVID-19 pandemic. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(5):7-15. (In Russ.). https://doi.org/10.17116/jnevro20201200517
Vasileva AE, Garifullina FT, Malkova AA. Asthenic-depressive syndrome in patients who have undergone COVID-19. Modern Science. 2022;4-3:24-27. (In Russ.). https://doi.org/10.1017/S2045796015000189
Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Journal of Clinical Psychiatry. 2008;69(4):514-519. https://doi.org/10.4088/jcp.v69n0401
Chen L-S, Eaton WW, Gallo JJ, Nestadt G. Understanding the heterogeneity of depression through the triad of symptoms, course and risk factors: a longitudinal, population-based study. Journal of Affective Disorders. 2000;59(1):1-11. https://doi.org/10.1016/s0165-0327(99)00132-9
Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiology and Psychiatric Sciences.2015;24(3):210-226.
Hamilton M. A rating scale for depression. Journal of neurology, neurosurgery, and psychiatry. 1960;23(1):56-62. https://doi.org/10.1136/jnnp.23.1.56
Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. In: US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health. 1976;76-338.